{"id":12675,"date":"2026-05-28T21:00:00","date_gmt":"2026-05-28T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=8c83ff57ed1c9e8c6399b265c6045aaf"},"modified":"2026-05-28T21:00:00","modified_gmt":"2026-05-28T19:00:00","slug":"medincell-videoconference-and-publication-of-annual-financial-results-tuesday-june-16-2026-2","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12675","title":{"rendered":"Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026"},"content":{"rendered":"

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:<\/p><\/a><\/a>

\nMedincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.<\/p>

\nThe presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.<\/p>

\nVideoconference in English, 6:00pm CEST \/ 12:00pm ET\n<\/b>>https:\/\/www.medincell.com\/annual-results-2025-2026-register\/<\/a><\/p>

\nVideoconference in French, 6:00pm CEST \/ 12:00pm ET\n<\/b>>https:\/\/www.medincell.com\/fr\/resultats-annuels-2025-2026-enregistrement\/<\/a><\/p>

\nDuring the videoconference, Medincell\u2019s management team will provide an overview of the company\u2019s performance and strategic outlook, followed by a Q&A session in English.<\/p>

\nAbout Medincell<\/b><\/p>

\nMedincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.<\/p>

\nThese treatments combine active pharmaceutical ingredients with our proprietary BEPO\u00ae<\/sup> \/ BEPO\u00ae<\/sup> Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.<\/p>

\nRisperidone LAI was the first treatment based on BEPO\u00ae<\/sup> technology to receive FDA approval, initially for schizophrenia in April 2023, and subsequently for Bipolar I Disorder in October 2025. It is marketed in the United States by Teva under the brand name UZEDY\u00ae<\/sup>. Medincell\u2019s risperidone LAI was also approved for schizophrenia in Canada and South Korea in 2025.<\/p>

\nA New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell\u2019s partner, Teva. U.S. FDA accepts Teva\u2019s New NDA for Olanzapine LAI on February 20, 2026.<\/p>

\nMedincell\u2019s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.<\/p>

\nHeadquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.<\/p>

\nmedincell.com<\/a><\/b><\/p>

\nUZEDY\u00ae<\/sup> is a trademark of Teva Pharmaceuticals. Medincell\u2019s BEPO\u00ae<\/sup> technology is licensed to Teva as SteadyTeq\u2122, a trademark of Teva Pharmaceuticals.<\/i><\/p>

\nThis press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities.<\/p>

\nThese statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as \"objective\", \"believe\", \"expect\", \"aim\", \"intend\", \"may\", \"anticipate\", \"estimate\", \"plan\", \"project\", \"will\", \"may\", \"probably\", \"should\", \"could\" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements.<\/p>

\nA list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorit\u00e9 des March\u00e9s Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements.<\/p>

\nThis press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.<\/p> Contacts<\/b>

\nDavid Heuz\u00e9<\/b>Head of Corporate and Financial Communications, and ESG\ndavid.heuze@Medincell.com<\/a> \/ +33 (0)6 83 25 21 86<\/p>

\nGrace Kim<\/b>Chief Strategy Officer, U.S. Finance\ngrace.kim@medincell.com<\/a> \/ +1 (646) 991-4023<\/p>

\nNicolas M\u00e9rigeau<\/b>Media Relations\nMedincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94<\/p>

\nLouis-Victor Delouvrier \/ Alban Dufumier<\/b>Investor Relations France\nMedincell@newcap.eu<\/a> \/ +33 (0)1 44 71 94 94<\/p>","protected":false},"excerpt":{"rendered":"

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:
\nMedincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconfer…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12675","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12675"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12675\/revisions"}],"predecessor-version":[{"id":12676,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12675\/revisions\/12676"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}